



TFW

PATENT
Attorney Docket 057971-5006-US

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Margherita T. Cantorna *et al.*
Application No. 10/674,395
Filing Date: **October 1, 2003**
For: **PPAR- γ Ligands in the Treatment of
Asthma and Allergies**

Group Art Unit: **1614**
Examiner: *To Be Assigned*

U.S. Patent and Trademark Office
220 20th Street S.
Customer Window
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. § 1.56 and § 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449. This Information Disclosure Statement is being filed, to the best of the undersigned's knowledge, before the mailing date of a first Office Action on the merits for the above-referenced application. Copies of the documents are included.

Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute prior art. If the Examiner applies any one of the documents as prior art against any claim in the application, and Applicants determine that the cited document does not constitute prior art under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be

applied against the claims of the present application.


This Information Disclosure Statement is filed under 37 C.F.R. §1.97(b) before the mailing of the first Office action on the merits in the application. No fee is believed to be due for this submission. If the U.S. Patent and Trademark Office deems a fee is due, please charge this fee and any other required fees to Morgan, Lewis & Bockius LLP Deposit Account No. 50-0310.

Dated: **June 8, 2004**
Morgan, Lewis & Bockius LLP
Customer No. **09629**
1111 Pennsylvania Avenue
Washington, D.C. 20004
202-739-3000

Respectfully submitted,
Morgan, Lewis & Bockius LLP


Suzanne E. Ziska
Registration No. 43,371

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)				ATTY DOCKET NO.		APPLICATION NO	
				057971-5006-US		10/674,395	
				APPLICANTS			
				Cantorna <i>et al.</i>			
				FILING DATE		GROUP	
				October 1, 2003		1614	
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	6,191,154 B1	02/20/2001	Landreth <i>et al.</i>	514	369	11/27/1998
	A02	6,214,850 B1	04/10/2001	Evans <i>et al.</i>	514	357	02/22/1999
	A03	6,605,627 B2	08/12/2003	Evans <i>et al.</i>	514	357	05/08/2002
	A04	6,413,994 B1	07/02/2002	Evans <i>et al.</i>	514	357	02/16/2001



OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
	C01	Benayoun, L., <i>et al.</i> , "Regulation of Peroxisome Proliferator-activated Receptor γ Expression in Human Asthmatic Airways," <i>Am. J. Respir. Crit. Care Med.</i> <u>164</u> :1487-1494, American Thoracic Society (2001)
	C02	Karol, M.H., "Animal models of occupational asthma," <i>Eur. Respir. J.</i> <u>7</u> :555-568, European Respiratory Society (1994)
	C03	Mueller, C., <i>et al.</i> , "Peroxisome proliferator-activated receptor γ ligands attenuate immunological symptoms of experimental allergic asthma," <i>Arch. Biochem. Biophys.</i> <u>418</u> :186-196, Elsevier Inc. (October 2003)
	C04	Serhan, C.N., and Devchand, P.R., "Novel Antiinflammatory Targets for Asthma. A Role for PPAR γ ?" <i>Am. J. Respir. Cell Mol. Biol.</i> <u>24</u> :685-661, American Thoracic Society (2001)
	C05	Zhang, Y., <i>et al.</i> , "A genome-wide screen for asthma-associated quantitative trait loci in a mouse model of allergic asthma," <i>Human Mol. Genet.</i> <u>8</u> :601-605, Oxford University Press (1999)

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	